Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients.
暂无分享,去创建一个
N. Powe | T. Meyer | T. Hostetter | J. Coresh | T. Shafi | M. Melamed | Seungyoung Hwang | T. Banerjee | X. Hai | J. Coresh | Tanushree Banerjee
[1] N. Powe,et al. Kt/Vurea and Nonurea Small Solute Levels in the Hemodialysis Study. , 2016, Journal of the American Society of Nephrology : JASN.
[2] Connie M. Rhee,et al. US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[3] T. Ikizler,et al. Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis – a randomized cross-over study , 2015, BMC Nephrology.
[4] J. Loscalzo,et al. Nitroglycerin and Nitric Oxide--A Rondo of Themes in Cardiovascular Therapeutics. , 2015, The New England journal of medicine.
[5] Daniel F. Freitag,et al. Asymmetric Dimethylarginine and Cardiovascular Risk: Systematic Review and Meta-Analysis of 22 Prospective Studies , 2015, Journal of the American Heart Association.
[6] A. Sahebkar,et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations , 2015, Scientific Reports.
[7] T. Meyer,et al. Approaches to uremia. , 2014, Journal of the American Society of Nephrology : JASN.
[8] David A. Drew,et al. Asymmetric dimethylarginine, race, and mortality in hemodialysis patients. , 2014, Clinical journal of the American Society of Nephrology : CJASN.
[9] D. Fliser,et al. Dimethylarginines ADMA and SDMA: the real water-soluble small toxins? , 2014, Seminars in nephrology.
[10] N. Shah,et al. Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor Asymmetric Dimethylarginine , 2013, Circulation.
[11] D. Hilfiker-Kleiner,et al. Effects of chronic SDMA infusion on glomerular filtration rate, blood pressure, myocardial function and renal histology in C57BL6/J mice. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[12] M. Boshtam,et al. Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial , 2013, PPAR research.
[13] A. Martínez‐Castelao,et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. , 2013, Journal of the American Society of Nephrology : JASN.
[14] P. Ueland,et al. Omega-3 Status and the Relationship between Plasma Asymmetric Dimethylarginine and Risk of Myocardial Infarction in Patients with Suspected Coronary Artery Disease , 2012, Cardiology research and practice.
[15] J. Leiper,et al. Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators? , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[16] M. Dew,et al. The association of mental health over time with cardiac outcomes in HEMO study patients. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[17] M. Bots,et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. , 2012, Journal of the American Society of Nephrology : JASN.
[18] J. Jankowski,et al. Guanidino Compounds as Cause of Cardiovascular Damage in Chronic Kidney Disease: An in vitro Evaluation , 2010, Blood Purification.
[19] A. Lichtenstein,et al. Altering dietary lysine:arginine ratio has little effect on cardiovascular risk factors and vascular reactivity in moderately hypercholesterolemic adults. , 2010, Atherosclerosis.
[20] A. Carter,et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. , 2010, Atherosclerosis.
[21] M. Margaglione,et al. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. , 2009, Atherosclerosis.
[22] R. Vanholder,et al. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[23] E. Benjamin,et al. Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community , 2009, Circulation.
[24] Raymond Vanholder,et al. Effect of membrane permeability on survival of hemodialysis patients. , 2009, Journal of the American Society of Nephrology : JASN.
[25] F. Dekker,et al. Symptom clusters in incident dialysis patients: associations with clinical variables and quality of life. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[26] J. Cooke,et al. Response to Letter Regarding Article, “L-Arginine Supplementation in Peripheral Arterial Disease: No Benefit and Possible Harm” , 2008 .
[27] T. Stijnen,et al. Review: a gentle introduction to imputation of missing values. , 2006, Journal of clinical epidemiology.
[28] J. Cooke,et al. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[29] G. Breithardt,et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. , 2006, Journal of the American Society of Nephrology : JASN.
[30] E. Schwedhelm,et al. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[31] D. Kass,et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. , 2006, JAMA.
[32] M. Rocco,et al. Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. , 2005, Nephrology, Dialysis and Transplantation.
[33] C. Zoccali,et al. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[34] S. Bode-Böger,et al. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. , 2005, Journal of the American Society of Nephrology : JASN.
[35] D. Fliser,et al. Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding. , 2004, Clinical nephrology.
[36] Francesco Locatelli,et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. , 2003, The New England journal of medicine.
[37] Sunil J Rao,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .
[38] Z. Varghese,et al. Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. , 2002, Kidney international.
[39] C. Zoccali,et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.
[40] D. Fliser,et al. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[41] T. Depner. Uremic Toxicity: Urea and Beyond , 2001, Seminars in dialysis.
[42] N W Levin,et al. Design and statistical issues of the hemodialysis (HEMO) study. , 2000, Controlled clinical trials.
[43] P. Kao,et al. Protein-arginine Methyltransferase I, the Predominant Protein-arginine Methyltransferase in Cells, Interacts with and Is Regulated by Interleukin Enhancer-binding Factor 3* , 2000, The Journal of Biological Chemistry.
[44] D. Pelligrino,et al. Effects of some guanidino compounds on human cerebral arteries. , 1999, Stroke.
[45] R. Foley,et al. Epidemiology of cardiovascular disease in chronic renal disease , 2000 .
[46] U. Förstermann,et al. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. , 1997, Nitric oxide : biology and chemistry.
[47] D. Heistad,et al. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. , 1995, The American journal of physiology.
[48] R. Macallister,et al. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis , 1994, British journal of pharmacology.
[49] S. Moncada,et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.
[50] E. Hur,et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[51] Hollis G. Potter,et al. Author Manuscript , 2013 .
[52] G. Beck,et al. Predictors of sudden cardiac death: a competing risk approach in the hemodialysis study. , 2012, American Society of Nephrology. Clinical Journal.
[53] Dustin R. Bunch,et al. A simple and fast liquid chromatography–tandem mass spectrometry method for measurement of underivatized l-arginine, symmetric dimethylarginine, and asymmetric dimethylarginine and establishment of the reference ranges , 2011, Analytical and Bioanalytical Chemistry.
[54] W. März,et al. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. , 2011, Clinical chemistry.
[55] M. Rocco,et al. Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[56] P. López-Jaramillo,et al. The L-arginine: nitric oxide pathway. , 1993, Current opinion in nephrology and hypertension.